Skip to content
value.today

T2 Biosystems, Inc.

Formerly Bioplex Systems, Inc.

Funding rounds

0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of T2 Biosystems, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2016$40 MPrivate placement after listing$10 to $50 million

T2 Biosystems, Inc.: Private sale, Sep 2016

Investors in this round

1 investor had bought by the notice of Sep 27, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for T2 Biosystems, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David P. Harding · Executive Officer · Chief Commercial Officer
  • Joanne Spadoro, Ph.D. · Executive Officer · Chief Operating Officer
  • John McDonough · Executive Officer, Director · Chief Executive Officer
  • Michael A. Pfaller, M.D. · Executive Officer · Chief Medical Officer
  • Michael M. Gibbs, Esq. · Executive Officer · Vice President and General Counsel
  • Rahul M. Dhanda · Executive Officer · Senior Vice President, Corporate Development
  • Shawn Lynch · Executive Officer · Chief Financial Officer
  • Steven M. Scampini · Executive Officer · Vice President, Engineering
  • Tom Lowery, Ph.D. · Executive Officer · Chief Scientific Officer
  • Adrian M. Jones · Director
  • David W. Elsbree · Director
  • John W. Cumming · Director
  • Josh A. Bilenker, M.D. · Director
  • Michael A. Cima, Ph.D. · Director
  • Seymour M. Liebman · Director
  • Stanley M. Lapidus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Gibbs, Esq., General Counsel. Source: SEC Form D, newest notice filed Sep 27, 2016. Read the notice at the SEC.

equitySEC
Mar 2013$400 MPrivate placement after listing$250 million to $1 billion

T2 Biosystems, Inc.: Private sale, Mar 2013

Investors in this round

16 investors had bought by the notice of Mar 28, 2013: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for T2 Biosystems, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$400 M of $400 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John McDonough · Executive Officer, Director
  • Thomas Lowery · Executive Officer
  • Alan Crane · Director
  • Harry Wilcox · Director
  • Josh Bilenker · Director
  • Michael Cima · Director
  • Michael Greeley · Director
  • Robert Langer · Director
  • Stacy Feld · Director
  • Stan Lapidus · Director
  • TJ Carella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John McDonough, President and CEO. Source: SEC Form D, newest notice filed Mar 28, 2013. Read the notice at the SEC.

equitySEC
Aug 2011$23 MPrivate placement after listing$10 to $50 million

T2 Biosystems, Inc.: Private sale, Aug 2011

Investors in this round

14 investors had bought by the notice of Aug 10, 2011: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for T2 Biosystems, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John McDonough · Executive Officer, Director
  • Thomas Lowery · Executive Officer
  • Alan Crane · Director
  • Harry Wilcox · Director
  • Josh Bilenker · Director
  • Michael Cima · Director
  • Michael Greeley · Director
  • Robert Langer · Director
  • Stacy Feld · Director
  • Stan Lapidus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John McDonough, President and CEO. Source: SEC Form D, newest notice filed Aug 10, 2011. Read the notice at the SEC.

equitySEC
May 2010$15 MPrivate placement after listing$10 to $50 million

T2 Biosystems, Inc.: Private sale, May 2010

Investors in this round

13 investors had bought by the notice of May 28, 2010: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for T2 Biosystems, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $20 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Wiesen · Executive Officer
  • John McDonough · Executive Officer, Director
  • Alan Crane · Director
  • Doug Levinson · Director
  • Michael Cima · Director
  • Michael Greeley · Director
  • Robert Langer · Director
  • Stan Lapidus · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John McDonough, President and CEO. Source: SEC Form D, newest notice filed May 28, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • T2 Biosystems, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2016).

    SEC Form D · Sep 2016

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Sep 2016

That is all the official record says: T2 Biosystems, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

24 named in official filings. Open an investor to see everything it has backed.

Investors in T2 Biosystems, Inc.
InvestorKindAmountRoundRoleSource
Aisling Capital III LPFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Aisling Capital Partners III LLCFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Aisling Capital Partners III LPFund or asset managernot statednot statedHeld Series D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Bridge Street 2013 Holdings, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Bridge Street 2013, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Bridge Street 2013 Offshore, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Bridge Street Opportunity Advisors, L.L.C.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Broad Street Principal Investments, L.L.C.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Flagship Ventures Fund 2004 L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Flagship Ventures Fund IV General Partner LLCVenture capitalnot statednot statedHeld Series A-1, A-2, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Flagship Ventures Fund IV, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Flagship Ventures General Partner LLCVenture capitalnot statednot statedHeld Series A-1, A-2, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Goldman Sachs & CoOthernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Goldman Sachs Group IncFund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
MBD 2013 Holdings, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
MBD 2013, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
MBD 2013 Offshore, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
MBD Advisors, L.L.C.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Michael J. CimaPersonnot statednot statedHeld Series E preferred stock, director (Form 3, 2014)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by T2 Biosystems, Inc.
NameRoleNamed in
David P. HardingChief Commercial OfficerSep 2016
Joanne Spadoro, Ph.D.Chief Operating OfficerSep 2016
John McDonoughChief Executive OfficerSep 2016
Michael A. Pfaller, M.D.Chief Medical OfficerSep 2016
Michael M. Gibbs, Esq.Vice President and General CounselSep 2016
Rahul M. DhandaSenior Vice President, Corporate DevelopmentSep 2016
Shawn LynchChief Financial OfficerSep 2016
Steven M. ScampiniVice President, EngineeringSep 2016
Tom Lowery, Ph.D.Chief Scientific OfficerSep 2016
Thomas LoweryExecutive officerMar 2013
Jeffrey WiesenExecutive officerMay 2010
Adrian M. JonesDirectorSep 2016
David W. ElsbreeDirectorSep 2016
John McDonoughChief Executive OfficerSep 2016
John W. CummingDirectorSep 2016
Josh A. Bilenker, M.D.DirectorSep 2016
Michael A. Cima, Ph.D.DirectorSep 2016
Seymour M. LiebmanDirectorSep 2016
Stanley M. LapidusDirectorSep 2016
Alan CraneDirectorMar 2013
Harry WilcoxDirectorMar 2013
Josh BilenkerDirectorMar 2013
Michael CimaDirectorMar 2013
Michael GreeleyDirectorMar 2013
Robert LangerDirectorMar 2013
Stacy FeldDirectorMar 2013
Stan LapidusDirectorMar 2013
TJ CarellaDirectorMar 2013
Doug LevinsonDirectorMay 2010